LeMaitre Vascular (NASDAQ:LMAT) Releases Q1 2025 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) updated its first quarter 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 0.480-0.530 for the period, compared to the consensus earnings per share estimate of 0.510. The company issued revenue guidance of $56.7 million-$58.7 million, compared to the consensus revenue estimate of $58.1 million. LeMaitre Vascular also updated its FY 2025 guidance to 2.150-2.320 EPS.

LeMaitre Vascular Stock Down 11.8 %

LeMaitre Vascular stock opened at $90.87 on Friday. The company’s 50-day moving average price is $96.90 and its two-hundred day moving average price is $94.66. The stock has a market cap of $2.04 billion, a P/E ratio of 49.01, a P/E/G ratio of 2.22 and a beta of 0.96. LeMaitre Vascular has a twelve month low of $62.39 and a twelve month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.49. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business had revenue of $55.81 million during the quarter, compared to the consensus estimate of $55.99 million. Equities analysts anticipate that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Barrington Research cut shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday. Oppenheimer cut LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday. StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Finally, Wells Fargo & Company initiated coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 price objective for the company. Five investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $94.63.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.